title: Effect of the kappa-opioid receptor agonist, U69593, on reinstatement of extinguished amphetamine self-administration behavior.
abstract: Previous research has indicated that pretreatment with the kappa-opioid receptor agonist, U69593, decreased the ability of experimenter-administered cocaine to reinstate extinguished cocaine self-administration behavior. This effect was specific to cocaine-produced drug seeking since U69593 failed to attenuate the ability of experimenter-administered amphetamine to reinstate extinguished cocaine self-administration behavior. One possibility is that U69593 selectively attenuates the behavioral effects of the drug that was originally self-administered. In order to test this hypothesis, the present study examined the effect of U69593 (0.0 or 0.32 mg/kg) on the reinstatement of extinguished amphetamine self-administration behavior produced by experimenter-administered injections of cocaine and amphetamine. Following extinction of amphetamine self-administration (0.04 mg/kg/infusion) the ability of cocaine (0.0, 5.0, 10.0 or 20.0 mg/kg) or amphetamine (0.0, 0.3, 1.0 or 3.0 mg/kg) to reinstate extinguished self-administration behavior was measured. Both drugs reinstated extinguished responding and the reinstatement was attenuated by pretreatment with U69593. The data indicate that the ability of U69593 to decrease drug seeking is not restricted to subjects experienced with cocaine self-administration. Self-administration history does, however, determine the effect of U69593 on amphetamine-produced drug seeking.
authors.affiliation: Texas A&M University Department of Psychology, College Station 77843, USA. sxs@psyc.tamu.edu
authors.forename: S
authors.initials: S
authors.lastname: Schenk
authors.forename: B
authors.initials: B
authors.lastname: Partridge
mesh_terms: D000661:Amphetamine / Q000008:administration & dosage*; D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D016739:Behavior, Addictive / Q000188:drug therapy*; D044482:Benzeneacetamides; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D003042:Cocaine / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D008297:Male; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017473:Receptors, Opioid, kappa / Q000819:agonists; D012646:Self Administration
chemical_list: D000700:Analgesics; D044482:Benzeneacetamides; D000697:Central Nervous System Stimulants; D018765:Dopamine Uptake Inhibitors; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; D000661:Amphetamine; D003042:Cocaine; C045444:U 69593